Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 7/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.45 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30883810 | 1.00 | EGFR (0.47) | EGFRMKNK2MKNK1CCNT1CDK9 | |
| SCHEMBL30883808 | 1.00 | EGFR (0.47) | EGFRMKNK2MKNK1CCNT1CDK9 | |
| SCHEMBL19114738 | 0.89 | EGFR (0.57) | EGFRMKNK2MKNK1CCNT1CDK9 | |
| SCHEMBL17384791 | 0.89 | EGFR (0.56) | EGFRMKNK2MKNK1CCNT1CDK9 | |
| SCHEMBL18607152 | 0.86 | MKNK2 (0.45) | EGFRMKNK2MKNK1CCNT1CDK9 | |
| SCHEMBL17822322 | 0.85 | EGFR (0.51) | EGFR | |
| SCHEMBL30883802 | 0.85 | EGFR (0.51) | EGFR | |
| SCHEMBL32671769 | 0.84 | MKNK1 (0.65) | EGFRMKNK2MKNK1 | |
| SCHEMBL17822349 | 0.84 | CCNT1 (0.51) | EGFRMKNK2MKNK1CCNT1CDK9 | |
| SCHEMBL29555980 | 0.84 | MKNK1 (0.65) | EGFRMKNK2MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112457298-B | Substituted 2-anilinopyrimidine derivatives and their use as epidermal growth factor receptor modulators | 贝达医药公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-112375067-B | Substituted 2-anilinopyrimidine derivatives and their use as epidermal growth factor receptor modulators | 贝达医药公司 | 2024-03-15 | — | — | CN | disclosed |
| US-11414401-B2 | Substituted 2-anilinopyrimidine derivatives as EGFR modulators | BETA PHARMA INC. (US) | 2022-08-16 | — | — | US | disclosed |
| CN-112457298-A | Substituted 2-anilinopyrimidine derivatives and their use as epidermal growth factor receptor modulators | 贝达医药公司 | 2021-03-09 | — | — | CN | disclosed |
| CN-112375067-A | Substituted 2-anilinopyrimidine derivatives and their use as epidermal growth factor receptor modulators | 贝达医药公司 | 2021-02-19 | — | — | CN | disclosed |
| CN-108024993-B | Substituted 2-anilinopyrimidine derivatives and their use as epidermal growth factor receptor modulators | 贝达医药公司 | 2020-11-06 | — | — | CN | disclosed |
| US-20200216421-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINE DERIVATIVES AS EGFR MODULATORS | BETA PHARMA, INC. (US) | 2020-07-09 | — | — | US | disclosed |
| US-10590111-B2 | Substituted 2-anilinopyrimidine derivatives as EGFR modulators | BETA PHARMA, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170362203-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINE DERIVATIVES AS EGFR MODULATORS | BETA PHARMA, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362203-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINE DERIVATIVES AS EGFR MODULATORS | BETA PHARMA, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362203-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINE DERIVATIVES AS EGFR MODULATORS | BETA PHARMA, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| EP-3229798-A2 | SUBSTITUTED 2-ANILINOPYRIMIDINE DERIVATIVES AS EGFR MODULATORS | Beta Pharma, Inc. (US) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016094821-A2 | SUBSTITUTED 2-ANILINOPYRIMIDINE DERIVATIVES AS EGFR MODULATORS | BETA PHARMA, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016094821-A2 | SUBSTITUTED 2-ANILINOPYRIMIDINE DERIVATIVES AS EGFR MODULATORS | BETA PHARMA, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10590111-B2 | Substituted 2-anilinopyrimidine derivatives as EGFR modulators | EGFR, ERBB2, ERBB4 | EGFR 1/4885MKNK2 1100/4885MKNK1 1174/4885 |
| US-20200216421-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINE DERIVATIVES AS EGFR MODULATORS | EGFR, ERBB2, ERBB4 | EGFR 1/4885MKNK2 1100/4885MKNK1 1174/4885 |
| US-11414401-B2 | Substituted 2-anilinopyrimidine derivatives as EGFR modulators | EGFR, ERBB2, ERBB4 | EGFR 1/4885MKNK2 1100/4885MKNK1 1174/4885 |
| US-20170362203-A1 | SUBSTITUTED 2-ANILINOPYRIMIDINE DERIVATIVES AS EGFR MODULATORS | EGFR, ERBB2, ERBB4 | EGFR 1/4885MKNK2 1100/4885MKNK1 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.